Some members of the CYP3A subfamily show gender-dependent expression. Using quantitative real-time polymerase chain reaction, we report that female rats have 28-fold higher CYP3A9 mRNA levels than males in liver and 3.8-fold higher in lung. Furthermore, the CYP3A9 expression profile in kidney exhibits a regio-specific distribution, i.e., a 10-fold higher expression in cortex compared with medulla. Also, we observed tissue-specific estrogen regulation of the CYP3A9 message. Estrogen treatment caused a significant up-regulation in liver and a marked down-regulation both in the cortex and medulla of the kidney. Upon ovariectomy, hepatic and brain CYP3A9 expression were reduced significantly, but a modest increase in kidney expression was observed. The effects of ovariectomy on CYP3A9 gene expression were reversed upon exogenous estrogen treatment. CYP3A protein levels and hepatic microsomal activity toward benzphetamine after various treatments showed changes parallel to CYP3A9 mRNA levels. We report for the first time that CYP3A9 levels change dramatically during the course of pregnancy.
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Cytochromes P450 (P450) comprise a superfamily of microsomal heme proteins that catalyze the oxidative metabolism of various endobiotics and xenobiotics (Wrighton et al., 1990) . The CYP3A subfamily, the most abundantly expressed among the P450 superfamily, is responsible for aspects of the metabolism of endogenous steroids such as testosterone, progesterone, lithocholic acid, and for the primary metabolism of more than 50% of clinically utilized drugs (Gillam et al., 1993; Yamazaki and Shimada, 1997; Wang et al., 2000) . Moreover, CYP3As play an important role in presystemic elimination of drugs and provide a mechanism for clinically observed drug-drug interactions (Moore et al., 2000) .
In rats, the CYP3A subfamily consists of five related genes, CYP3A1, CYP3A2, CYP3A9, CYP3A18, and CYP3A23. Although these isoforms are predominantly expressed in liver (Komori and Oda, 1994) , extrahepatic expression in brain (Wang et al., 1996) , intestine (Watkins, 1992) , kidneys (Debri et al., 1995) , leukocytes (Mahnke et al., 1996) , and lungs has also been reported. In addition, CYP3As in rats show sex-, tissue-, species-, and age-dependent expression patterns (Waxman et al., 1995) . For instance, CYP3A2 expression is observed only in neonatal female rats, while it is demonstrable throughout the life-cycle of male rats (Gonzalez et al., 1986) . Likewise, CYP3A1 and CYP3A18 have been shown to be male-dominant isoforms (Strotkamp et al., 1995) .
Using Northern blot analysis, our laboratory previously reported that hepatic CYP3A9 expression was 10-fold higher in females than in male rats (Wang and Strobel, 1997) . Subsequently, several other studies, using RTPCR, reported a 2-to 6-fold higher expression in female rats (Mahnke et al., 1997; Robertson et al., 1998) . These mRNA expression profiles would classify CYP3A9 distribution as female-dominant rather than female-specific according to the definition of Kato and Yamazoe (1993) . To clarify this discrepancy, we developed a quantitative real-time PCR (QRTPCR) assay that would enable a more precise quantitation of CYP3A9 levels. QRTPCR has been used recently to distinguish among various closely related P450 isoforms (Burczynski et al., 2001; Kalsotra et al., 2002) .
In this study we defined the extrahepatic expression profile of CYP3A9 and determined more precisely the difference between male and female CYP3A9 gene expression. The regulation of CYP3A9 expression by progesterone (PROG) and estrogen (E 2 ) was also evaluated. The catalytic capacity of microsomes from control, ovariectomized (OVEX), and OVEX plus E 2 -treated rats was analyzed to examine further the correlation between CYP3A9 expression and CYP3A9 function. Finally, to investigate whether CYP3A9 showed altered levels in pregnant rats, ward primer, 200 nM reverse primer, 4 mM MgCl 2 , 1.25 U/50 l Taq polymerase, and 150 nM fluorogenic probe) were added to 10 l of the RT reaction. Amplification was performed using an ABI Prism 7700 (Applied Biosystems) at 95°C for 1 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Standard curves were generated by plotting Ct versus the log of the amount of amplicon (custom-made from IDT Inc.) specific for CYP3A9 (20 attograms-2 pg), and were used to compare the relative amount of CYP3A9 mRNA in the samples. Data were analyzed by the use of the Sequence Detection Application and relative values of mRNA also were generated by normalizing copy number values of CYP3A9 to the copy number values of rat cyclophilin.
Preparation of Microsomes. Microsomes from different tissues were prepared as previously described by Saito and Strobel (1981) . Briefly, tissues were homogenized (20 strokes) in 6 volumes of potassium phosphate buffer (pH 7.4) containing 20 mM KPi, 0.25 M sucrose, 1 mM EDTA, and a cocktail of protease inhibitors (1 mM PMSF, 1 g/ml leupeptin, and 0.7 g/ml pepstatin). Each homogenate was centrifuged at 8500 rpm for 20 min and the supernatant fraction was collected. The supernatant fraction was further centrifuged at 100,000g for 45 min; the pellet washed in fresh buffer, and again centrifuged at 100,000g for 45 min. The washed pellets were resuspended in the homogenate buffer and stored at Ϫ80°C until analysis.
Western Blotting. The total protein concentration in microsomes was determined by BCA assay using bovine serum albumin (BSA) as the standard. Samples were boiled in Laemmli buffer and resolved on 4 to 15% gradient Tris-glycine sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS PAGE) gels. Proteins were transferred to nitrocellulose membranes using a semidry transfer apparatus. Membranes were blocked for 4 h with 5% dried nonfat milk in TTBS (0.05% Tween 20 in Tris-buffered saline) followed by an overnight incubation at 4°C in 1:1000 dilution of polyclonal rabbit anti-rat primary antibody raised against CYP3A2, which recognizes most CYP3A forms. Membranes were then washed and incubated at room temperature with HRP-conjugated goat anti-rabbit secondary antibody (1:1000 dilution) for 2 h. Immunoreactivity was detected using an HRP chemiluminescence system (Pierce, Rockford, IL).
Activity Assays. The N-demethylation assay for benzphetamine was performed in a final volume of 2 ml with 100 mM potassium phosphate buffer (pH 7.7), containing an aliquot of microsomal protein, and 1 mM benzphetamine HCl. The reaction was initiated by the addition of NADPH to a final concentration of 1 mM (SigmaAldrich) and incubated at 37°C for 10 min and terminated by addition of 17.5% perchloric acid. The fluorimetric measurement of the formaldehyde product formation was carried out as described previously (Wang and Strobel, 1997) .
Statistical Analysis. Data are presented as mean Ϯ S.E. Statistical significance for differences in CYP3A9 expression between male and female groups was determined using a two-tailed unpaired Student's t test. Multiple groups in the OVEX, hormonal, or pregnancy study were compared using one-way analysis of variance (ANOVA). Statistical differences were considered significant if P Ͻ 0.05. Primers and probes were designed using Primer Express software (Applied Biosystems) at the 3Ј-untranslated region of the CYP3A9 gene since this region is highly differentiable among all CYP3A isoforms. Similarly, R-cyclophilin primers and probe were also designed using Primer Express software.
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Results
Tissue Distribution of CYP3A9. QRTPCR analysis revealed 28-fold higher CYP3A9 expression in female than in male rat livers (Fig. 1a) , thus making CYP3A9 female-specific according to Kato and Yamazoe (1993) . CYP3A9 was predominantly expressed in liver followed by lung, which showed 3.8-fold higher expression in females (P Ͻ 0.05), while renal CYP3A9 levels were equally distributed in rats of either sex. CYP3A9 is also expressed in male and female brain. We can summarize the tissue distribution as liver Ͼ Ͼ lung Ͼ kidney ϳ brain (Table 2) . Furthermore, within the kidney we observed a regio-selective distribution of CYP3A9 with a 10-fold higher expression in cortex compared with medulla ( Fig. 1b) .
Effects of E 2 on CYP3A9 Expression. Upon treatment of female rats with 250 g/kg E 2 we observed 20-fold induction of hepatic CYP3A9 mRNA expression compared with controls. Doubling the dose of E 2 to 500 g/kg did not increase CYP3A9 expression any further compared with lowdosed rats (Fig. 2) . Conversely, 250 g/kg E 2 treatment led to a 10-fold decrease of CYP3A9 message in renal cortex. CYP3A9 levels in cortex could not be detected at a 500 g/kg dose of estradiol. Medullary CYP3A9 expression in the kidney was completely eliminated even at the 250 g/kg E 2 treatment. Thus, we observed opposite effects on hepatic and renal CYP3A9 levels upon exogenous E 2 treatments. In brain, no significant change in CYP3A9 message level was observed following E 2 treatment (Fig. 2) .
Effects of Ovariectomy and Hormone Treatment. To examine further the effects of E 2 on CYP3A9 gene expression, animals were OVEX, and treated with PROG (50 mg/ kg), E 2 (250 g/kg), or both. We observed a marked decrease in CYP3A9 mRNA levels in liver and brain of OVEX animals. In kidney, however, we found a modest increase in CYP3A9 expression after OVEX (Table 2) . Exogenous E 2 treatment reversed the OVEX effects in liver such that CYP3A9 levels were significantly higher than controls. E 2 treatment, however, could not restore CYP3A9 expression in brain after OVEX. Again, renal CYP3A9 exhibited a dramatic downregulation upon E 2 treatment in OVEX animals. PROG, however, could partially restore CYP3A9 levels in liver. Brain CYP3A9 expression was not altered after PROG treatment. The combined dosing of E 2 and PROG averaged the effects of individual treatments in all the tissues used in this study (Table 2) .
Northern Hybridization Analysis. To validate the QRTPCR results, we performed Northern blot analysis using rat liver RNA from various treatment groups. We observed similar patterns of expression as reported earlier using QRT-PCR assays. The Northern blot shown in Fig. 3 depicts diminished CYP3A9 mRNA expression in OVEX animals compared with controls, which can be returned to control levels by E 2 treatment. PROG, however, does not show such a drastic increase in expression, and the dual hormone treatment appears to average their individual effects on CYP3A9 mRNA levels.
CYP3A9 Expression Pattern during Pregnancy. To determine CYP3A9 mRNA levels during the course of pregnancy, we analyzed day 13-, day 19-, and day 21-pregnant rats. The data suggest that hepatic and brain CYP3A9 message levels vary as pregnancy progresses, reaching the highest level of expression during late pregnancy. Also, it is interesting to note that hepatic CYP3A9 mRNA levels significantly decreased during early stages of pregnancy when compared with nonpregnant controls. The CYP3A9 level of day 13-pregnant animals was 0.94 Ϯ 0.34 (% R-cyclophilin) while the nonpregnant animals showed 67.5 Ϯ 24.9 (% Rcyclophilin) values. On day 19, CYP3A9 expression in liver was increased 2-fold when compared with day 13. On day 21, CYP3A9 mRNA expression levels in liver showed a significant 28-fold increase when compared with day 13. On the contrary, renal CYP3A9 expression was decreased significantly on day 19 and day 21 (Fig. 4) . In brain, we observed a significant increase in CYP3A9 mRNA levels on day 21 when compared with day 19 (Fig. 4) .
CYP3A Protein Levels after Hormone Treatments. The data clearly show that E 2 affects the regulation of CYP3A9 at the mRNA level. To examine whether the message translates to consequent fluctuations in CYP3A9 pro- Fig. 1 . a, gender-biased tissue distribution of CYP3A9. Total RNA from various rat tissues (n ϭ 4) of either sex was prepared and assayed using QRTPCR. Each sample was normalized to R-cyclophilin and represented as percent male. ‫,ء‬ P Ͻ 0.05 compared with male CYP3A9 values. b, regional distribution of CYP3A9 in kidney cortex versus medulla. Total RNA from cortex and medulla (n ϭ 4) was prepared and assayed for CYP3A9 using QRTPCR. R-cyclophilin served as the internal standard. ‫,ء‬ P Ͻ 0.05 compared with cortex CYP3A9 values.
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From the data shown in Fig. 5 , it is evident that CYP3A protein levels in liver reduced significantly after OVEX and was restored upon E 2 treatment. The degree of this change in protein levels corresponds to the change in mRNA expression and is consistent with the notion that in female rat liver, CYP3A9 constitutes a major portion of CYP3A protein expressed since all other rat CYP3A forms are male-dominant (Mahnke et al., 1997; Robertson et al., 1998) . On the contrary, renal microsomes exhibited a significant increase in CYP3A protein levels upon OVEX, which was reduced to control amounts after E 2 treatment. Thus, the protein changes observed were consistent with the changes observed in CYP3A9 mRNA levels.
CYP3A Catalytic Activity. N-Demethylation activity toward benzphetamine was measured to assess functional endpoints of the changes observed in the CYP3A protein levels. Hepatic microsomes were incubated with the substrate and the catalytic capacity was determined as described under Materials and Methods. The specific activity toward benzphetamine in microsomes from OVEX rats was significantly reduced in comparison to control, and was partially restored in E 2 -treated OVEX rats (Fig. 6) . Similar results were seen when ethylmorphine was used as a substrate (data not shown). It should be noted, however, that changes in microsomal N-demethylation activities do not follow as closely to the changes in either CYP3A protein levels or CYP3A9 mRNA expression after various treatments. This is consistent with expectation since apart from CYP3As, benzphetamine N-demethylation is also catalyzed by the CYP1, CYP2, and CYP4 families to varying extents. Therefore, changes in total microsomal benzphetamine demethylation reflect the sum of all contributing families.
Discussion
QRTPCR has been used recently by many groups to study P450 induction and expression patterns in cultured rat hepatocytes and in vivo animal models (Bowen et al., 2000; Burczynski et al., 2001; Kalsotra et al., 2002) . QRTPCR assays were standardized and utilized to quantitate CYP3A9 message in rats. In terms of tissue distribution, maximum expression of CYP3A9 was observed in liver, which is the primary site for all phase I drug metabolism, followed by lung and equivalent levels of expression in kidney and brain. Furthermore, our results indicate a regio-selective CYP3A9 expression in kidney in favor of cortex over medulla. We have seen such regioselectivity with CYP4F family members, also. It seems reasonable that P450 levels are higher in cortex where glomerular filtration and resorption occurs, accounting for a protective role against drug-induced renal toxicity.
Sex-dependent expression of cytochromes P450 and their influence on drug metabolism and drug toxicity have been previously observed. Animal experiments, principally in rats, have revealed that expression of a number of P450 enzymes is sex-dependent (Waxman et al., 1995; Wang and Strobel, Fig. 3 . Northern blot hybridization for hepatic CYP3A9 mRNA expression. Total RNA from OVEX and hormone treated rat tissues was prepared and transferred to nitrocellulose membrane and hybridized with a 309-bp CYP3A9-specific radiolabeled probe. The blot was stripped and re-probed with rat cyclophilin to assess equal sample loading. Fig. 2 . Effects of varying estrogen treatment on CYP3A9 expression. Rats (n ϭ 4) were treated with two doses of E 2 250 g/kg or 500 g/kg as described under Materials and Methods. Total RNA from both E 2 treated animals and controls were analyzed for CYP3A9 expression using QRT-PCR assay with R-cyclophilin as an internal standard. ‫,ء‬ P Ͻ 0.05 compared with control.
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1997; Kalsotra et al., 2002) . The present study was performed in part to verify whether CYP3A9 truly exhibits sexually dimorphic expression in favor of females. We observed a 28-fold higher hepatic CYP3A9 expression in female rats than males, consistent with a 10-fold higher response published earlier using Northern blot techniques (Wang and Strobel, 1997) . Also, CYP3A9 showed a 3.8-fold higher expression in lung. On the contrary, rat CYP3A1, CYP3A18 (Robertson et al., 1998) , and CYP3A2 (Mahnke et al., 1997) are expressed in a male-dominant manner. Several players, including growth hormone, have been implicated in genderspecific expression of cytochrome P450 3As, which in turn are influenced by steroid hormones such as E 2 and testosterone (Kawai et al., 2000) . More recently, involvement of Signal Transducer and Activators of Transcription (STAT) family members, namely STAT 5a and STAT 5b, in growth hormone-mediated sexually dimorphic expression of genes has been reported (Park et al., 1999) . To understand the mechanism of gender specific CYP3A9 regulation we treated OVEX rats with female sex hormones E 2 and PROG. The data suggest that E 2 can differentially regulate hepatic and renal CYP3A9 in a tissue-specific manner. After OVEX, the absence of E 2 leads to significant downregulation of CYP3A9 mRNA levels in liver and brain, but a marked increase in kidney. These responses could be reversed by exogenous E 2 treatment in liver but not to the same extent with PROG. It is known that E 2 can cause both positive and negative regulation and tissue-selective responses through its receptors (Pettersson et al., 2000; Hall et al., 2001) . The predominant biological effects of E 2 are mediated through its receptors ER ␣ and ER ␤ . In rats, ER ␣ shows high expression in liver, kidney, testis, and ovaries, whereas ER ␤ is predominant in brain, lung, bladder, and epididymis (Kuiper et al., 1996) . The distribution of estrogen receptors ␣ and ␤ in different tissues could offer one possible explanation for tissue-specific E 2 response (Diel, 2002) .
Unlike the reduced expression of hepatic CYP3A9 after OVEX, the reduced CYP3A9 levels in the brain could not be restored with exogenous E 2 . This result is in contrast to the previous report from our laboratory which showed using a PCR southern analysis, that brain CYP3A9 was partially restored upon E 2 treatment (Wang and Strobel, 1997) . The QRTPCR technique used in the present study is more sensitive than PCR southern analysis and provides a better quan- Fig. 4 . mRNA levels of CYP3A9 during pregnancy. Tissues from day 13-, day 19-, and day 21-pregnant animals were analyzed for CYP3A9 mRNA levels. R-cyclophilin served as an internal standard and CYP3A9 mRNA levels are expressed in terms of nonpregnant control levels. Four animals per group were used for this experiment. ‫,ء‬ P Ͻ 0.05 when day 13 is compared with day 19; ‫,ءء‬ P Ͻ 0.05 when day 13 is compared with day 21; #, P Ͻ 0.05 when day 19 is compared with day 21.
Fig. 5.
Immunoblot of microsomes for CYP3A expression. OVEX rats (n ϭ 4) in each group were treated with hormones, as described under Materials and Methods. A, microsomes were prepared and analyzed for CYP3A protein expression using anti-CYP3A2 antibody. B, the membranes after transfer were Ponceau-stained to ensure equal protein transfer. a, CYP3A protein expression in liver microsomes. b, CYP3A protein expression in renal microsomes. Fig. 6 . CYP3A specific activity measured in liver microsomes using benzphetamine as substrate. Microsomes from liver were prepared from OVEX and hormone-treated groups of rats (n ϭ 4), as described under Materials and Methods. Formaldehyde assays were performed to evaluate CYP3A-mediated N-demethylation of benzphetamine in different groups. ‫,ء‬ P Ͻ 0.05 when compared with the control; ‫,ءء‬ P Ͻ 0.05 when compared with OVEX.
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at ASPET Journals on July 8, 2017 jpet.aspetjournals.org Downloaded from titation of CYP3A9 mRNA levels. Also, while E 2 readily penetrates the blood-brain barrier, it is not retained by this organ, necessitating constant intracranial dosing to achieve sustained and pharmacologically relevant brain concentrations (Bodor and Buchwald, 1999) . Furthermore, transporters such as P-glycoprotein (Rao et al., 1994) , organic anion transporter peptide-2, and organic anion transporters (Sugiyama et al., 2001) can effectively efflux steroid hormones across the blood-brain barrier. This could partially explain the inability of the exogenous E 2 regimen to restore the decreased CYP3A9 levels in brain upon OVEX.
We also examined the response of different concentrations of E 2 on CYP3A9 mRNA levels in different tissues and found no linear correlation between the two doses used and CYP3A9 expression. This may imply that the E 2 saturates at concentrations near a 500 g/kg daily dose.
Another dramatic finding of this study is that CYP3A9 expression changed drastically in a tissue-specific manner throughout the course of pregnancy. The hepatic mRNA levels of CYP3A9 decreased on day 13 and day 19 of pregnancy when compared with the nonpregnant rats, but increased significantly on day 21 compared with day 13. This decrease in CYP3A9 levels could be due to suppression of CYP3A9 message by high plasma PROG levels reached during early pregnancy (Gaspar et al., 2001) . This is also true with our data seen in OVEX animals treated with E 2 and PROG, where the up-regulation exhibited with E 2 treatment is reduced significantly in liver when both PROG and E 2 are used. An analogous antagonistic role for PROG is observed in cytochrome P450 2D mRNA expression (Baum and Strobel, 1997) . These data are also consistent with the recent finding that demonstrates a 4-fold increase in ER ␣ expression in liver from day 15 to day 21 while ER ␤ remains fairly constant (Okada et al., 2002) . Moreover, plasma E 2 levels increase significantly to 500 pmol on day 21 as compared with 250 pmol on day 14 and day 19 of pregnancy (Gaspar et al., 2001) . This increase provides a putative basis for the increased hepatic CYP3A9 expression seen at day 21 compared with day 14 or day 19.
Based on the above results, the ability of E 2 to modulate CYP3A protein and its catalytic activity was investigated. In the absence of a monoclonal CYP3A9 antibody a polyclonal anti-CYP3A2 antibody was used. The CYP3A protein levels from liver and kidney changed in an analogous fashion to that of CYP3A9 message after OVEX followed by the different hormone treatments. These observations demonstrate that CYP3A9 mRNA regulation by E 2 is also reflected downstream at the protein level. In addition, the activity data correlated well with the observed changes in mRNA and protein levels upon OVEX followed by hormonal regimen, suggesting that these changes have metabolic consequences for drug treatments as well as for steroid metabolism.
The existence of sex-dependent differences in drug metabolism is not unique to rats. Such differences have been reported in humans (Hunt et al., 1992) . Therefore, elucidating the underlying mechanism of E 2 regulation of CYP3A9 and its differential tissue-specific responses may help us gain insights into the mechanisms that lead to gender-associated differences in human therapeutic responses seen after treatment of men and women with the same drug (Rademaker, 2001) . Since CYP3As are clinically relevant drug metabolizing enzymes, and are responsive to hormone levels, it is important to consider CYP3A status during different stages of pregnancy because the plasma concentrations of drugs administered during this period can significantly oscillate with the varying CYP3A levels.
